| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |